4.5 Review

Assessment of Histologic Disease Activity in Crohn's Disease: A Systematic Review

期刊

INFLAMMATORY BOWEL DISEASES
卷 20, 期 11, 页码 2092-2103

出版社

OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0000000000000155

关键词

Crohn's disease; histology; indices; outcome measures; disease activity; clinical trials; systematic review

资金

  1. Abbott
  2. ActoGeniX NV
  3. AGI Therapeutics Inc.
  4. Alba Therapeutics Corp.
  5. Albireo
  6. Alfa Wasserman
  7. Amgen
  8. AM-Pharma BV
  9. Anaphore, Astellas
  10. Athersys Inc.
  11. Atlantic Healthcare Ltd.
  12. Aptalis, BioBalance Corp.
  13. Boehringer-Ingelheim
  14. Bristol-Myers Squibb
  15. Celgene
  16. Celek Pharmaceuticals
  17. Cellerix SL
  18. Cerimon Pharmaceuticals
  19. Chemo-Centryx
  20. CoMentis
  21. Cosmo Technologies
  22. Coronado Biosciences
  23. sCytokine Pharmascience
  24. Eagle Pharmaceuticals
  25. EnGene Inc
  26. Eli Lilly
  27. Enteromedics
  28. Exagen Diagnostics Inc.
  29. Ferring Pharmaceuticals
  30. Flexio Therapeutics Inc.
  31. Funxional Therapeutics Ltd
  32. Genzyme Corp.
  33. Gilead Sciences
  34. Given Imaging
  35. GSK
  36. Human Genome Sciences
  37. Ironwood Pharmaceuticals
  38. KaloBios Pharmaceuticals
  39. Lexicon Pharmaceuticals
  40. Lycera Corp.
  41. Meda Pharmaceuticals
  42. Merck Research Laboratories
  43. Merck Serono
  44. Millenium Pharmaceuticals
  45. Nisshin Kyorin Pharmaceuticals
  46. Novo Nordisk
  47. NPS Pharmaceuticals
  48. Optimer Pharmaceuticals
  49. Orexigen Therapeutics Inc.
  50. PDL Biopharma
  51. Pfizer
  52. Procter and Gamble
  53. Prometheus Laboratories
  54. ProtAb Ltd.
  55. Purgenesis Technologies Inc.
  56. Relypsa Inc.
  57. Roche
  58. Salient Pharmaceuticals
  59. Salix Pharmaceuticals
  60. Santarus
  61. Schering Plough
  62. Shire Pharmaceuticals
  63. Sigmoid Pharma Ltd.
  64. Sirtris Pharmaceuticals
  65. SLA Pharma UK Ltd.
  66. Targacept
  67. Teva Pharmaceuticals
  68. Therakos
  69. Tillotts Pharma AG
  70. TxCell SA
  71. UCB Pharma
  72. Viamet Pharmaceuticals
  73. Vascular Biogenics Ltd.
  74. Warner Chilcott UK Ltd.
  75. Wyeth
  76. BristolMyers Squibb
  77. Genentech
  78. Janssen
  79. Milennium Pharmaceuticals
  80. Novartis

向作者/读者索取更多资源

Background: Crohn's disease (CD) is an idiopathic, chronic, transmural inflammatory disorder of the gastrointestinal tract. Because mucosal involvement is near-universal, endoscopic healing has emerged as an important aspect in improving outcome. However, resolution of histologic disease activity has potential to convey additional benefit beyond that attained with endoscopic healing alone. Validated scoring systems of histologic disease activity are required to further assess this possibility. The aim of this study was to systematically review the existing histologic disease activity indices (HDAI) for CD and to assess their operating properties and potential use as outcome measures in clinical trials. Methods: MEDLINE (Ovid), EMBASE (Ovid), PubMed, the Cochrane Library (CENTRAL), and Digestive Disease Week (DDW) abstracts were searched from 1981 to April 2013 for applicable studies to identify relevant studies for review and analysis. Results: In total, 3732 citations were screened to obtain 89 articles for inclusion. Sixty-six HDAIs were characterized as either stepwise or numerical instruments. These HDAIs were used for either assessment of response to medical therapy or for comparison with biomarkers or imaging tests. None of the HDAIs identified was developed according to currently accepted methods for developing evaluative instruments, and none have been formally validated. Conclusions: Measurement of histologic disease activity has potential value in CD; however, no validated measures are available. Additional research is needed to develop a methodologically rigorous instrument for use in clinical investigation and potentially for clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据